P985: CLL-1 IS AN ADOPTIVE IMMUNOTHERAPY TARGET IN JUVENILE MYELOMONOCYTIC LEUKEMIA

por Huebner, Juwita, Xirenayi, Sherin, Rivera, Jose, Patiño Escobar, Bonell, Lee, Alex G, Mandal, Kamal, Diaz-Flores, Ernesto, Wiita, Arun, Stieglitz, Elliot
Publicado 2023

CD22(low)/Bcl-2(high) expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia

por Wintering, Astrid, Ishiyama, Kenichi, Tamaki, Stanley, Tamaki, Courtney, Fandel, Joshua, Ji, Lingyun, Wood, Brent L., Shah, Nirali N., Yuan, Constance M., O’Brien, Maureen M., Loh, Mignon L., Diaz-Flores, Ernesto
Publicado 2022

Cooperative loss of RAS feedback regulation drives myeloid leukemognesis

por Zhao, Zhen, Chen, Chi-Chao, Rillahan, Cory D., Shen, Ronglai, Kitzing, Thomas, McNerney, Megan E., Diaz-Flores, Ernesto, Zuber, Johannes, Shannon, Kevin, Le Beau, Michelle M., Spector, Mona S., Kogan, Scott C., Lowe, Scott W.
Publicado 2015

Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia

por Pariury, Holly, Fandel, Joshua, Bachl, Stefanie, Ang, Kenny K., Markossian, Sarine, Wilson, Chris G., Braun, Benjamin S., Popescu, Bogdan, Wohlfeil, Margo, Beckman, Kyle, Xirenayi, Simayijiang, Roy, Ritu P., Olshen, Adam B., Smith, Catherine, Arkin, Michelle R., Loh, Mignon L., Diaz-Flores, Ernesto
Publicado 2023

Response and Resistance to MEK Inhibition in Leukaemias Initiated by Hyperactive Ras

por Lauchle, Jennifer O., Kim, Doris, Le, Doan T., Akagi, Keiko, Crone, Michael, Krisman, Kimberly, Warner, Kegan, Bonifas, Jeannette M., Li, Qing, Coakley, Kristin M., Diaz-Flores, Ernesto, Gorman, Matthew, Przybranowski, Sally, Tran, Mary, Kogan, Scott C., Roose, Jeroen P., Copeland, Neal, Jenkins, Nancy, Parada, Luis, Wolff, Linda, Sebolt-Leopold, Judith, Shannon, Kevin
Publicado 2009